Schedule M: Over 100 Pharma MSMEs in Telangana on the Brink of Closure

The Revised Schedule M, a set of GMP guidelines for pharmaceutical production, has been a game-changer for the industry.

The Health Master

July 24, 2024

Table of Contents

Last Updated on July 24, 2024 by The Health Master

Schedule M

The pharmaceutical manufacturing landscape in Telangana is on the verge of a seismic shift due to revised Schedule M compliance.

Over a hundred Micro, Small, and Medium Enterprises (MSMEs) in the state are poised to shutter their operations within the next three months, as the stringent requirements of the Revised Schedule M prove insurmountable.

Follow us on WhtasApp Channel

Schedule M Compliance: A Mountain to Climb

The Revised Schedule M, a set of Good Manufacturing Practices (GMP) guidelines for pharmaceutical production, has been a game-changer for the industry.

While larger pharma companies have managed to adapt to the new norms, smaller players are struggling to keep their heads above water.

Massive Investment: Upgrading facilities to meet Schedule M standards requires a hefty investment of Rs. 5 to 10 crore per unit.
Revenue Crunch: MSMEs are facing a dire financial situation, with many unable to generate the minimum Rs. 50 crore annual turnover necessary to sustain operations after compliance.

Click for more Articles on Pharmaceuticals

Click for more Legal Articles on Pharmaceuticals

Industry in Distress: A Cry for Help

Faced with an uncertain future, the Telangana chapter of the Indian Drug Manufacturers Association (IDMA) has sounded the alarm.

President J Rajamouli led a delegation to the Director-General of Drugs Control Administration, seeking a temporary reprieve from inspections.

Intense Scrutiny: Drug control officials have been conducting frequent inspections, adding to the industry’s woes.
Temporary Relief: While the DG has agreed to halt inspections until December 2024, the long-term outlook remains bleak.

Click for Guidance documents for industry

No Extension in Sight: A Do-or-Die Situation

The Central Drugs Standard Control Organization (CDSCO) has shown no inclination to extend the deadline for Schedule M compliance.

This leaves MSMEs with a stark choice: adapt or perish.

High Failure Rate: A staggering 36% of inspected manufacturing units have been forced to close due to non-compliance.
Industry-Wide Plea: Pharmaceutical associations across India have urged the CDSCO for a one-year extension, but their requests have fallen on deaf ears.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Click below links for more articles on Revised Schedule M

Schedule M

Gist of 31 Chapters on Schedule M

Revised Schedule M Guidelines: Drug Recall and Ensuring Pharma Quality

Pharmaceutical Quality: Key Amendments in Revised Schedule M

Revised Schedule M: The Role of Pharmaceutical Waste Management

Must read

Inspections to be started for compliance of Revised Schedule M: Tamil Nadu

Gujarat FDCA Equips Pharma Industry for Revised Schedule M

New Schedule M: Impact on Cosmetic Manufacturing

CDSCO underscores stringent compliance to Revised Schedule M

Can Your Air Handling Meet the new Schedule M? Find Out Here